Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Lucie Ellis
Erytech's lead therapy has shown strong anti-cancer activity in pancreatic cancer, on top of the hematological indications it is already targeting in late-stage trials, spelling good news for the French firm to pursue more studies in other oncology indications such as ovarian cancer.
Newron has reported positive Phase IIa data for schizophrenia drug evenamide but Phase III will be critical for the add-on therapy to demonstrate a more robust treatment effect to justify its use on top current treatments.
Orphan drug development used to be considered a license to print money, with high price tags and a focused customer base. With the development of an increasingly tough orphan drug pricing environment in the US and Europe, biotechs are adopting new strategies. CNS drug developer Minoryx will introduce endpoints into its Phase II/III studies for rare brain disease X-ALD that should help demonstrate both efficacy and value for future pricing discussions.
The microbiome market will see its value rise to $500m by 2022, and higher during the next decade. The key driver will be the increase in biotech and pharma firms looking at the emerging research space for new therapeutic options to treat chronic conditions such as Crohn’s disease.
New NICE and NHS England appraisal rules regarding timelines and price thresholds could fast-track new cost-effective drugs but then delay them from reaching patients for up to three years. The new regulations, which will come into force in April, have raised a lot of questions around methodology and impact outside of England.
New NICE and NHS England appraisal rules regarding timelines and price thresholds – labeled stark and contradictory – could fast-track new cost-effective drugs but then subject the same products to significant delays of multiple years.